About Prosetta
Prosetta is a Healthcare company based in Mysuru (India) founded in 2004 by Karl Manheim. It operates as a biotech firm discovers small-molecule drugs for viral, bacterial infections, cancers, and neurodegenerative diseases. It operates on a B2B and Licensing model. Its Indian entity Prosetta Bio-Conformatics Private Limited reported revenue of ₹1.18 Cr. Prosetta offers products and services including Broad-Spectrum Antibiotics and Small-Molecule Drugs. Its focus areas include Biotechnology, Drug Discovery, Infectious Diseases and Oncology. Similar companies include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte and 4 more; 8 of its 9 listed similar companies have raised funding.
Company details
Prosetta Bioconformatics, established in 2004, is a biotech research company based in Mysuru, India, with a parent company in San Francisco, USA. It focuses on discovering and developing novel small-molecule drugs targeting viral, bacterial infections, cancers, and neurodegenerative disorders using its unique Prosetta Paradigm platform. The company advances programs for broad-spectrum antibiotics and collaborates with pharmaceutical firms through licensing agreements, conducting efficacy studies and in-vitro research to address global health challenges.
- Headquarters Mysuru, India
- Founders Karl Manheim
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website prosetta.co.in
- Legal Name Prosetta Bio-Conformatics Private Limited
- Date of Incorporation 03 Mar, 2004
- Jurisdiction Mysore, Karnataka, India
- Annual Revenue₹1.18 Cr
FY 2024 · -11% YoY
- Net Profit₹10.3 Lakh
FY 2024 · 9% margin
- EBITDA₹28.5 Lakh
FY 2024 · 24% margin
Associated legal entities of Prosetta
Prosetta operates through Prosetta Bio-Conformatics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Prosetta Bio-Conformatics Private Limited CIN U51397KA2004PTC033501 | Active | 03 Mar 2004 | Mysore, Karnataka | ₹1.2 Cr | – | 4 | View details |
Products & Services of Prosetta
Prosetta offers a comprehensive portfolio of products and services, including Broad-Spectrum Antibiotics and Small-Molecule Drugs.
Drugs targeting multi-drug resistant pathogens for community infections.
Compounds for viral infections and cancers via novel mechanisms.
Board of directors of Prosetta Bio-Conformatics Private Limited (Prosetta)
Prosetta Bio-Conformatics Private Limited is the primary company behind Prosetta. The board of Prosetta Bio-Conformatics Private Limited currently have 4 directors; the longest-serving is Vishwanath Rao Lingappa, appointed in 2004.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vishwanath Rao Lingappa DIN 02272426 | Director | 03 Mar 2004 | 22 yrs 7 mo | Prosetta Bio-Conformatics Private Limited |
| Karl Michael Manheim DIN 02234843 | Director | 03 Mar 2004 | 22 yrs 7 mo | Prosetta Bio-Conformatics Private Limited |
| Nisrani Hosmane Ramakrishna DIN 02744329 | Director | 30 Jun 2007 | 19 yrs 3 mo | Prosetta Bio-Conformatics Private Limited |
| Mahadevappa Dharma Prasad DIN 02327449 | Director | 30 Jun 2007 | 19 yrs 3 mo | Prosetta Bio-Conformatics Private Limited |
People of Prosetta
1 people are tracked at Prosetta (1 in leadership).
| Name | Role | Group |
|---|---|---|
| Co-Founder | Leadership |
Complete people profiles for Prosetta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Prosetta
Figures of Prosetta Bio-Conformatics Private Limited, the primary company behind Prosetta, for FY 2024. Revenue was ₹1.18 Cr (-11% year on year). Net profit was ₹10.3 Lakh (9% margin). EBITDA was ₹28.5 Lakh (24% margin). Revenue has grown at a compounded annual rate of -7% over three years and -8% over five years.
- ₹1.18 CrRevenue · FY 2024 · -11% YoY
- ₹10.3 LakhNet profit · 9% margin
- ₹28.5 LakhEBITDA · 24% margin
- ₹21.8 LakhPaid-up capital
- -7%Revenue CAGR, 3 years
- -8%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Prosetta Bio-Conformatics Private Limited are on its company page.
Detailed financial statements for Prosetta
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Prosetta
Prosetta has 9 listed similar companies in our database, 8 of them funded. They include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed similar companies of Prosetta
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
10 companies that operate in the same segment as Prosetta (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | 172 | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | 329 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Prosetta
Prosetta was founded in 2004.
Prosetta is headquartered in Mysuru, India. It is registered at Mysuru, Karnataka, India.
The primary company behind Prosetta, Prosetta Bio-Conformatics Private Limited, reported revenue of ₹1.18 Cr for FY 2024, down 11% year on year.
Prosetta Bioconformatics, established in 2004, is a biotech research company based in Mysuru, India, with a parent company in San Francisco, USA. It focuses on discovering and developing novel small-molecule drugs targeting viral, bacterial infections, cancers, and neurodegenerative disorders using its unique Prosetta Paradigm platform. The company advances programs for broad-spectrum antibiotics and collaborates with pharmaceutical firms through licensing agreements, conducting efficacy studies and in-vitro research to address global health challenges.
Prosetta's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Prosetta offers Broad-Spectrum Antibiotics and Small-Molecule Drugs.
Prosetta operates through Prosetta Bio-Conformatics Private Limited.
The legal entities of Prosetta currently have 4 directors, including Vishwanath Rao Lingappa, Nisrani Hosmane Ramakrishna, Karl Michael Manheim and others.